N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
Ovarian Cancer · Peritoneal Neoplasms · Fallopian Tube Cancer
Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities
Phase 3 N=144 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76
N/A N=10 Speech Hero Home Therapy for Aphasia
Broca Aphasia
Primary: Number of Participants That Used the Device for at Least Ten Hours Over the Course of Four Weeks — 7 Participants
Phase 2 N=287 A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Depressive Disorder, Major
Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.3; -12.2; -15.0; -14.7 score on a scale — p=0.724
N/A N=7 Opioid Taper Study
Chronic Pain
Primary: Pain Perception Measured Using the Cold-pressor Test (CPT) — 24.01; 42.02 seconds
Phase 2 N=61 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
Hepatic Cirrhosis · Liver Fibrosis
Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…
Phase 3 N=437 Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Acute Schizophrenia
Primary: PANSS Total Score Mean Change From Baseline to Endpoint — -24.6; -24.7; -11.0 units on a scale
Phase 2 N=134 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Phase 3 N=219 Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…
Phase 3 N=140 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Ovarian Cancer
Primary: Efficacy Patient Level — 26.9 percentage of participants
Phase 4 N=109 The Effects of ADHD Medication (TEAM) Study
ADHD
Primary: Parent ADHD Total Symptom Scores — 36.2; 34.6; 17.6; 15.3 score on a scale — p=0.55
Phase 2 N=44 Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
COVID-19
Primary: Time to Participant Recovery — 6; 12 days
Phase 3 N=1,180 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
COVID-19 · SARS-CoV2
Primary: Percentage of Participants With COVID-19 — 15.7; 8.3 Percentage of Participants — p=<0.001
N/A N=32 Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients
Chronic Hepatitis C
Primary: Percentage of Patients Consented Versus Approached — 74 percentage of participants